TABLE 5

Model independent mean pharmacokinetic parameters for the plasma concentrations obtained on day 6 following oral administration of VX-509 q.d. or b.i.d.; n = 6 per dose group

CompoundRegimenDoseAUC0_12h (±S.E.)Tmax (±S.E.)Cmax (±S.E.)Tlast (±S.E.)Clast (±S.E.)t1/2 (±S.E.)
mg/kgµM × hhµMhµMh
VX-509b.i.d.1010.8 (±3.6)1 (±0.33)3.4 (±1,3)12 (±0)0.2 (±0.05)3.12 (±1.6)
VX-509b.i.d.2521.4 (±4.5)1 (±0)7.2 (±1.8)12 (±0)0.2 (±0.07)2.2 (±0.1)
VX-509b.i.d.5071.1 (±7.8)1 (±0.3)12.1 (±1.1)12 (±0)0.6 (±0.2)2.4 (±0.4)
VX-509q.d.50102.5 (±0.6)1 (±0.3)19.3 (±1.2)12 (±0)0.5 (±0.2)1.94 (±0.2)
VX-509q.d.100170.5 (±7.4)1 (±0)33.6 (±5)12 (±0)2.7 (±0.9)3.15 (±0.8)
  • AUC, area under the curve; Clast, concentration at last measurement; Tlast, time at last measurement.